


What is claimed is:

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

A is $-C(O)-$, $-C(S)-$, $-CH_2-$, $-CH(C_1-C_4 \text{ alkyl})-$, or $-C(C_1-C_4 \text{ alkyl})(C_1-C_4 \text{ alkyl})-$;

n is an integer ranging from 0 to 3;

each R_1 is independently $-(C_1-C_3)\text{alkyl}$, $-O-(C_1-C_3)\text{alkyl}$, $-\text{halo}$, $-C(\text{halo})_3$, $-\text{CH}(\text{halo})_2$, $-\text{CH}_2(\text{halo})$, $-\text{NO}_2$, $-\text{OH}$, or $-\text{CN}$;

when A is $-CH_2-$, $-CH(C_1-C_4 \text{ alkyl})-$, or $-C(C_1-C_4 \text{ alkyl})(C_1-C_4 \text{ alkyl})-$, then R_2 is $-\text{phenyl}$, $-\text{naphthyl}$, or $-(C_{14})\text{aryl}$, each of which is unsubstituted or substituted with one or more R_4 groups, or, when A is $-C(O)-$ or $-C(S)-$, then R_2 is

(i) $-\text{H}$, $-(C_1-C_{10})\text{alkyl}$, $-(C_2-C_{10})\text{alkenyl}$, $-(C_2-C_{10})\text{alkynyl}$, $-(C_3-C_{10})\text{cycloalkyl}$, $-(C_8-C_{14})\text{bicycloalkyl}$, $-(C_8-C_{14})\text{tricycloalkyl}$, $-(C_5-C_{10})\text{cycloalkenyl}$, $-(C_8-C_{14})\text{bicycloalkenyl}$, $-(C_8-C_{14})\text{tricycloalkenyl}$, $-(3\text{- to }7\text{-membered})\text{heterocycle}$, or $-(7\text{- to }10\text{-membered})\text{bicycloheterocycle}$, each of which, other than $-\text{H}$, is unsubstituted or substituted with one or more R_5 groups, or

(ii) $-\text{phenyl}$, $-\text{naphthyl}$, $-(C_{14})\text{aryl}$, or $-(5\text{- to }10\text{-membered})\text{heteroaryl}$, each of which is unsubstituted or substituted with one or more R_4 groups;

p is an integer ranging from 0 to 2;

each R₃ is independently -OH, -halo, -NO₂, -CN, -NH₂, -(C₁-C₃)alkyl, or -CH₂OH;

each R₄ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl,

-(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃,

-CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₆)₂, -CH=NR₆, -NR₆OH, -COR₆,

5 -C(O)OR₆, -OC(O)R₆, -OC(O)OR₆, -SR₆, -S(O)R₆, or -S(O)₂R₆;

each R₅ is independently -CN, -OH, -halo, -N₃, -NO₂, -N(R₆)₂, -CH=NR₆, -NR₆OH,

-COR₆, -C(O)OR₆, -OC(O)R₆, -OC(O)OR₆, -SR₆, -S(O)R₆, or -S(O)₂R₆; and

each R₆ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl,

-(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(C₃-C₅)heterocycle, -C(halo)₃,

10 -CH(halo)₂, or -CH₂(halo); and

each halo is independently -F, -Cl, -Br, or -I.

2. The compound of claim 1, wherein p is 0 or 1.

15 3. The compound of claim 1, wherein A is -CH₂-.

4. The compound of claim 1, wherein A is -CH(C₁-C₄ alkyl)-.

5. The compound of claim 1, wherein A is -C(C₁-C₄ alkyl)(C₁-C₄ alkyl)-.

20

6. The compound of claim 1, wherein A is -C(O)-.

7. The compound of claim 6, wherein R₂ is -H, -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl,

-(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-

25 C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-

membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is

unsubstituted or substituted with one or more R₅ groups.

8. The compound of claim 6, wherein R₂ is -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₄ groups.

5 9. The compound of claim 8, wherein R₂ is -phenyl.

10. The compound of claim 9, wherein the phenyl is substituted in its 4-position with an R₄ group.

10 11. The compound of claim 1, wherein A is -C(S)-.

12. The compound of claim 11, wherein R₂ is -H, -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-
15 membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups.


13. The compound of claim 11, wherein R₂ is -phenyl, -naphthyl, -(C₁₄)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₄
20 groups.

14. The compound of claim 13, wherein R₂ is -phenyl.

15. The compound of claim 14, wherein the phenyl is substituted in its 4-position
25 with an R₄ group.

16. The compound of claim 1 having the formula (Ia):

5



(Ia)

10 or a pharmaceutically acceptable salt thereof, wherein R_1 and R_1' are independently -H, $-(C_1-C_3)\text{alkyl}$, $-O-(C_1-C_3)\text{alkyl}$, -halo, $-C(\text{halo})_3$, $-\text{CH}(\text{halo})_2$, $-\text{CH}_2(\text{halo})$, $-\text{NO}_2$, -OH, or -CN.

17. The compound of claim 16, wherein R_1 and R_1' are independently $-(C_1-C_3)\text{alkyl}$, $-O-(C_1-C_3)\text{alkyl}$, or -halo.

15

18. The compound of claim 17, wherein A is $-\text{C}(\text{O})-$.

19. The compound of claim 17, wherein A is $-\text{C}(\text{S})-$.

20

20. The compound of claim 17, wherein A is $-\text{CH}_2-$.

21. The compound of claim 17, wherein A is $-\text{CH}(C_1-C_4 \text{ alkyl})-$.

22. The compound of claim 17, wherein A is $-\text{C}(C_1-C_4 \text{ alkyl})(C_1-C_4 \text{ alkyl})-$.

25

23. The compound of claim 17, wherein R_1 is $-\text{CH}_3$ and R_1' is -Cl.

24. The compound of claim 17, wherein R_1 is $-CH_3$ and R_1' is $-OCH_3$.
25. The compound of claim 16, wherein R_1 and R_1' are $-(C_1-C_3)alkyl$.
- 5 26. The compound of claim 25, wherein R_1 and R_1' are $-CH_3$.
27. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
- 10 28. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16 and a pharmaceutically acceptable carrier or excipient.
- 15 29. A method for treating pain, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.
- 20 30. The method of claim 29, further comprising administering to the animal an effective amount of another therapeutic agent.
31. A method for treating pain, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.
- 25 32. The method of claim 31, further comprising administering to the animal an effective amount of another therapeutic agent.

33. A method for treating an addictive disorder, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

5 34. The method of claim 33, further comprising administering to the animal an effective amount of another therapeutic agent.

35. A method for treating an addictive disorder, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable
10 salt of the compound of claim 16.

36. The method of claim 35, further comprising administering to the animal an effective amount of another therapeutic agent.

15 37. A method for treating Parkinson's disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

38. The method of claim 37, further comprising administering to the animal an
20 effective amount of another therapeutic agent.

39. A method for treating Parkinson's disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.

25

40. The method of claim 39, further comprising administering to the animal an effective amount of another therapeutic agent.

41. A method for treating anxiety, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

5 42. The method of claim 41, further comprising administering to the animal an effective amount of another therapeutic agent.

43. A method for treating anxiety, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the
10 compound of claim 16.

44. The method of claim 43, further comprising administering to the animal an effective amount of another therapeutic agent.

15 45. A method for treating schizophrenia, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

46. The method of claim 45, further comprising administering to the animal an
20 effective amount of another therapeutic agent.

47. A method for treating schizophrenia, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the
25 compound of claim 16.

48. The method of claim 47, further comprising administering to the animal an effective amount of another therapeutic agent.

49. A method for inhibiting mGluR5-receptor function in a cell, comprising contacting a cell capable of expressing mGluR5 with an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

5 50. The method of claim 49, further comprising contacting the cell with an effective amount of another therapeutic agent.

51. A method for inhibiting mGluR5-receptor function in a cell, comprising contacting a cell capable of expressing mGluR5 with an effective amount of a compound or a
10 pharmaceutically acceptable salt of the compound of claim 16.

52. The method of claim 51, further comprising contacting the cell with an effective amount of another therapeutic agent.

15 53. A method for preparing a composition, the method comprising admixing a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

54. A kit comprising a container containing the composition of claim 27.
20